TARLATAMAB
Information current as at: 1 September 2026
PBAC meeting date: September 2026
Submission Details
- Brand name:
-
- Imdelltra®
- Form and strength:
-
- Powder for injection 1mg, powder for injection 10 mg
- Submission sponsor:
- AMGEN AUSTRALIA PTY LIMITED
- Condition/indication:
(therapeutic use) -
- To reconsider a request for listing tarlatamab for the second-line and subsequent treatment of adult patients with extensive-stage small cell lung cancer whose disease has progressed on or after platinum-based chemotherapy.
- Listing requested:
- Please see PSD for more information
- Funding program:
- PBS Section 100 (Efficient Funding of Chemotherapy)
- Request authority level:
- Authority Required (STREAMLINED)
- PBAC Submission type:
- New PBS listing (Early resolution)
- Comment:
- --
- Other PBAC consideration:
Progress Details
-
Submission received for: - September 2026 PBAC meeting
-
Opportunity for consumer comment: - Open 19/11/2025 and close 21/01/2026 (see PBS Website)
-
3PBAC meeting:
- Has not yet occurred
-
4PBAC outcome published:
- Pending PBAC outcome (see PBAC Outcomes)
-
5Lodgement of required documentation:
- Has not yet commenced
-
6Agreement to listing arrangements:
- Has not yet commenced
-
7Government processes:
- Has not yet commenced
-
8Medicine listed on the PBS:
- Has not yet occurred
PBAC Outcome
Case ID
a1319
Page last updated
31 August 2026
v.9.19